Analysts forecast that Teligent Inc (NASDAQ:TLGT) will report $17.73 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Teligent’s earnings. The highest sales estimate is $17.80 million and the lowest is $17.65 million. Teligent reported sales of $16.10 million during the same quarter last year, which indicates a positive year over year growth rate of 10.1%. The business is scheduled to issue its next quarterly earnings results before the market opens on Monday, March 18th.

On average, analysts expect that Teligent will report full year sales of $67.32 million for the current year, with estimates ranging from $67.24 million to $67.40 million. For the next year, analysts expect that the business will post sales of $85.10 million, with estimates ranging from $84.80 million to $85.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Teligent.

Separately, ValuEngine upgraded Teligent from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.

Teligent stock opened at $1.40 on Thursday. Teligent has a 12-month low of $1.13 and a 12-month high of $4.52. The company has a current ratio of 1.31, a quick ratio of 0.86 and a debt-to-equity ratio of 3.30. The stock has a market capitalization of $78.51 million, a price-to-earnings ratio of -7.37 and a beta of 1.59.

A number of institutional investors have recently added to or reduced their stakes in TLGT. Raymond James & Associates boosted its stake in shares of Teligent by 21.9% during the fourth quarter. Raymond James & Associates now owns 36,700 shares of the company’s stock valued at $50,000 after purchasing an additional 6,600 shares in the last quarter. New Jersey Better Educational Savings Trust boosted its stake in shares of Teligent by 11.1% during the fourth quarter. New Jersey Better Educational Savings Trust now owns 100,000 shares of the company’s stock valued at $137,000 after purchasing an additional 10,000 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Teligent by 0.7% during the third quarter. Vanguard Group Inc now owns 2,249,427 shares of the company’s stock valued at $8,885,000 after purchasing an additional 15,800 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Teligent by 0.5% during the third quarter. BlackRock Inc. now owns 3,463,605 shares of the company’s stock valued at $13,681,000 after purchasing an additional 16,198 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Teligent by 15.9% in the third quarter. Wells Fargo & Company MN now owns 123,329 shares of the company’s stock worth $488,000 after acquiring an additional 16,919 shares during the period. Hedge funds and other institutional investors own 64.73% of the company’s stock.

About Teligent

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Featured Article: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.